Clinical Trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Protocol Amendment History 4 changes
notable Trial sites expanded: 152 -> 164 locations 2026-07-29
notable Trial sites expanded: 146 -> 152 locations 2026-07-07
notable Trial sites expanded: 129 -> 146 locations 2026-05-23
notable Trial sites expanded: 120 -> 129 locations 2026-05-13
Trial Details
NCT Number NCT06161025
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Solid Cancer
Enrollment 860 participants
Start Date 2024-02-27
Primary Completion 2028-02-29 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28